Abstract
Editor's note: Nonarteritic anterior ischemic optic neuropathy (NAION), a form of optic nerve stroke, has received attention as the result of a possible rare association with PDE5 inhibitors (PDE5i). The possible mechanism of the PDE5i interaction with NAION is unclear, and the sporadic case reports do not seem to shed light on this topic. There is little guidance on this subject for the patient and clinician alike. Nonetheless, clinicians are being deluged with queries, without definitive answers. At this juncture, an ophthalmologic evaluation is discretionary, and appears to be based on either patient desire, patient risk factor profile, or clinician instinct. The scientific literature is scant as well. Several case reports exist to date, without clear vision for the future study of this disease. Robert Tomsak, a noted neuro-ophthalmologist, discusses NAION here.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Acknowledgements
I acknowledge the constructive comments of Robert B Daroff, MD.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tomsak, R. PDE5 inhibitors and permanent visual loss. Int J Impot Res 17, 547–549 (2005). https://doi.org/10.1038/sj.ijir.3901396
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijir.3901396
This article is cited by
-
Phosphodiesterase type 5 inhibitors, visual changes, and nonarteritic anterior ischemic optic neuropathy: Is there a link?
Current Urology Reports (2007)
-
Response to Tomsak, R. PDE5 inhibitors and permanent visual loss (Int J Impot Res 2005; 17: 547–549)
International Journal of Impotence Research (2006)